» Articles » PMID: 35677742

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

Abstract

Background: The fracture pathophysiology associated with type 2 diabetes and chronic kidney disease (CKD) is incompletely understood. We examined individual fracture predictors and prediction sets based on different pathophysiological hypotheses, testing whether any of the sets improved prediction beyond that based on traditional osteoporotic risk factors.

Methods: Within the CREDENCE cohort with adjudicated fracture outcomes, we assessed the association of individual factors with fracture using Cox regression models. We used the Akaike information criteria (AIC) and Schwartz Bayes Criterion (SBC) to assess six separate variable sets based on hypothesized associations with fracture, namely, traditional osteoporosis, exploratory general population findings, cardiovascular risk, CKD-mineral and bone disorder, diabetic osteodystrophy, and an all-inclusive set containing all variables.

Results: Fracture occurred in 135 (3.1%) participants over a median 2.35 [1.88-2.93] years. Independent fracture predictors were older age (hazard ratio [HR] 1.04, confidence interval [CI] 1.01-1.06), female sex (HR 2.49, CI 1.70-3.65), previous fracture (HR 2.30, CI 1.58-3.34), Asian race (HR 1.74, CI 1.09-2.78), vitamin D therapy requirement (HR 2.05, CI 1.31-3.21), HbA1c (HR 1.14, CI 1.00-1.32), prior cardiovascular event (HR 1.60, CI 1.10-2.33), and serum albumin (HR 0.41, CI 0.23-0.74) (lower albumin associated with greater risk). The goodness of fit of the various hypothesis sets was similar (AIC range 1870.92-1849.51, SBC range 1875.60-1948.04).

Conclusion: Independent predictors of fracture were identified in the CREDENCE participants with type 2 diabetes and CKD. Fracture prediction was not improved by models built on alternative pathophysiology hypotheses compared with traditional osteoporosis predictors.

Citing Articles

Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis.

Liu Y, Zhang Z, Fu C, Ye Z, Jin H, Yang X BMC Nephrol. 2025; 26(1):68.

PMID: 39934684 PMC: 11818153. DOI: 10.1186/s12882-025-03992-w.


The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease.

Aleksova J, Ebeling P, Elder G Nat Rev Endocrinol. 2025; .

PMID: 39820573 DOI: 10.1038/s41574-024-01083-8.


Vertebral fractures in patients with CKD and the general population: a call for diagnosis and action.

Gifre L, Masso E, Fusaro M, Haarhaus M, Urena P, Cozzolino M Clin Kidney J. 2024; 17(8):sfae191.

PMID: 39099567 PMC: 11294886. DOI: 10.1093/ckj/sfae191.


Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.

Hsu S, Bansal N, Denburg M, Ginsberg C, Hoofnagle A, Isakova T J Bone Miner Res. 2024; 39(4):433-442.

PMID: 38477777 PMC: 11262146. DOI: 10.1093/jbmr/zjae021.


Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.

Cipriani C, Lauriero G, Tripepi G, Ferrari S, Bover J, Ravera M J Clin Med. 2023; 12(23).

PMID: 38068310 PMC: 10707671. DOI: 10.3390/jcm12237260.

References
1.
Valderrabano R, Linares M . Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. Clin Diabetes Endocrinol. 2018; 4:9. PMC: 5918531. DOI: 10.1186/s40842-018-0060-9. View

2.
Naylor K, McArthur E, Leslie W, Fraser L, Jamal S, Cadarette S . The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014; 86(4):810-8. DOI: 10.1038/ki.2013.547. View

3.
Malmgren L, McGuigan F, Christensson A, Akesson K . Kidney function and its association to imminent, short- and long-term fracture risk-a longitudinal study in older women. Osteoporos Int. 2019; 31(1):97-107. PMC: 6946753. DOI: 10.1007/s00198-019-05152-x. View

4.
Ninomiya T, Perkovic V, de Galan B, Zoungas S, Pillai A, Jardine M . Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20(8):1813-21. PMC: 2723977. DOI: 10.1681/ASN.2008121270. View

5.
Tang H, Li D, Zhang J, Hsu Y, Wang T, Zhai S . Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016; 18(12):1199-1206. DOI: 10.1111/dom.12742. View